KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
Sí 98%
Calidad del mercado
45 / 100
Baja calidadVolumen 24h
644,8 €
Liquidez
1,9 mil €
Baja liquidezCompra / Venta
77.0% / 99.0%
Spread
22.0 pt
Spread amplioDatos de mercado
Actualizado hace 5 minutos
17 jun 26, 21:00 UTC1 ene 27, 4:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Venglustat by Sanofi (in 2026)
KalshiFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketReglas
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Liquida mediante:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep.
- It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions.
- This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Mercados abiertos
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 18,3 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volumen total
- 1,6 M €
- Volumen 24h
- 5,2 mil €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 resultados más
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volumen total
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volumen total
- 916 mil €
- Volumen 24h
- 1,5 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 resultados más
- Volumen total
- 863,6 mil €
- Volumen 24h
- 1 mil €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Kalshi cotiza Yes al 98% a fecha de 8 de septiembre de 2026.
- ¿Cuándo se resuelve FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Está previsto que FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Kalshi liquida este mercado del siguiente modo: If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.